Objective: To explore the association between metabolic syndrome and atherosclerosis.
Methods: Carotid intima-media thickness (IMT) was detected and the atherosclerotic plaque was classified, graded, and scored in 358 retired males, aged 55 approximately 74, including 95 (26.6%) with metabolic syndrome (metabolic syndrome group) and 263 (73.5%) without metabolic syndrome (non-metabolic syndrome group). The correlation of IMT with every characteristic of metabolic syndrome diagnostic criteria was studied.
Results: The metabolic syndrome group had higher carotid IMT (0.90 mm +/- 0.12 mm versus 0.84 mm +/- 0.11 mm, P < 0.05), plaque score (3.58 mm +/- 0.44 mm vs 2.45 mm +/- 0.25 mm, P < 0.05), plaque occurrence rate (64.2% vs 47.5%, P < 0.05) and cardiovascular event morbidity (20.0% versus 12.2%, P < 0.05) compared with the non-metabolic syndrome group. IMT was significantly but weakly positively correlated with systolic blood pressure, diastolic blood pressure, glucose, and waistline (r = 0.27, r = 0.17, r = 0.17 and r = 0.12 respectively, all P < 0.05).
Conclusion: Metabolic syndrome accelerates the course of atherosclerosis. Detecting carotid artery as early as possible by vascular ultrasound is helpful to primary prevention of cardiovascular events in the patients with metabolic syndrome.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of adrenal tumors and analysis of the metabolic profile of patients with incidentaloma.
Rev Col Bras Cir
January 2025
- Universidade Federal do Estado do Rio de Janeiro, Departamento de Cirurgia Geral - Serviço de Cirurgia Oncológica HUGG/EBSERH - Rio de Janeiro - RJ - Brasil.
Introduction: Advances in imaging methods have led to an increasingly frequent diagnosis of adrenal gland lesions as incidental findings. Despite progress in this field, there is still limited information regarding the epidemiology of the clinical and metabolic profile of patients with adrenal incidentaloma (AI). The objective is analyze the epidemiology of adrenal tumors at Gaffrée e Guinle University Hospital (HUGG) and compare it with data from the literature.
View Article and Find Full Text PDFMetabolic dysfunction-associated liver disease and biliary lithiasis in children with Down Syndrome: a retrospective study.
Rev Paul Pediatr
January 2025
Universidade Federal do Paraná, Curitiba, PR, Brazil.
Objective: To investigate the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) and gallbladder abnormalities in a sample of people with Down syndrome in Brazil.
Methods: This is a retrospective study using medical charts involving Down syndrome patients, diagnosed by karyotype, aged over 5 years, who underwent abdominal ultrasound and were monitored by the same professional in a clinic in Curitiba, Brazil. Data spanned January 1995 to September 2023; all cases with no use of alcohol or hepatotoxic medications.
Prevalence of metabolic syndrome among pregnant women: a systematic review and meta-analysis.
Endocrine
January 2025
Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
Purpose: Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of cardiometabolic diseases. The prevalence of MetS and individual components across pregnancy has not been reviewed in the literature. This research was conducted to identify the prevalence of MetS and its components among pregnant women.
View Article and Find Full Text PDFA Case of Rafiq Syndrome (MAN1B1-CDG) in a Palestinian Child, With Brief Literature Review of 44 Cases.
J Investig Med High Impact Case Rep
January 2025
Faculty of Medicine and Health Sciences, Palestine Polytechnic University, Hebron, Palestine.
Rafiq syndrome, MAN1B1-CDG, was described in 2010 and associated with genetic mutation in MAN1B1 gene in 2011. The disorder follows an autosomal recessive pattern of inheritance and typically presents with specific facial dysmorphism, intellectual disability, developmental delay, obesity, and hypotonia. The syndrome belongs to a group of metabolic disorders called Congenital Glycosylation Disorders (CGD).
View Article and Find Full Text PDFThe safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database.
Front Pediatr
January 2025
Department of Urology, The Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, China.
Objective: This study aimed to systematically evaluate the safety of cyclosporine (CsA) and tacrolimus (TAC) in pediatric nephrotic syndrome (NS) patients using real-world data from the FDA Adverse Event Reporting System (FAERS).
Methods: We analyzed adverse event (AE) reports from the FAERS database between Q4 2003 and Q2 2024, focusing on AEs associated with CsA and TAC in NS patients aged 18 years and younger. We employed three signal detection methods-Proportional Reporting Ratio (PRR), Relative Reporting Ratio (RRR), and Reporting Odds Ratio (ROR)-to assess the risk of drug-related AEs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!